ISSN: 2578-4625
Authors: Nandagopal M* and Krishna K
BCR-ABL1 is a gene sequence expressed in an abnormal copy of chromosome 22 in people who are diagnosed with certain forms of leukaemia. Molecular monitoring with BCR-ABL real-time quantitative Polymerase chain reaction (RQ-PCR) for assessing treatment success and quantifying minimal residual disease (MRD) is a crucial determinant of practical therapeutic decisionmaking in chronic disease management. Chronic myelogenous leukaemia (CML) and several other leukaemia’s, unlike other malignancies, are caused by a single, particular genetic mutation in one chromosome. This review article assesses CML, TKI response in targeted CML therapy, and data interpretation in molecular diagnosis. It highlights the purpose, application, and likely future of PCR-based molecular surveillance.
Keywords: BCR/ABL; Leukaemia; RQ-PCR; Molecular Diagnosis
